Palvella Therapeutics (PVLA) Common Equity (2013 - 2026)
Palvella Therapeutics (PVLA) reported Common Equity of $232.3 million for Q1 2026, up 318.0% year-over-year from $55.6 million in Q1 2025, and up 730.19% on a QoQ basis from $28.0 million in Q4 2025.
Palvella Therapeutics (PVLA) has 14 years of Common Equity data on file, last reported at $232.3 million in Q1 2026.
- Quarterly Common Equity rose 318.0% year-over-year to $232.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $232.3 million (up 318.0% YoY) and the FY2025 annual result came in at $28.0 million, down 55.3% from the prior year.
- Common Equity improved to $232.3 million in Q1 2026 per PVLA's latest filing, from $28.0 million in the prior quarter.
- Across five years, Common Equity topped out at $317.5 million in Q3 2022 and bottomed at -$93.8 million in Q4 2022.
- The 5-year median for Common Equity is $38.7 million (2025), against an average of $32.5 million.
- The widest annual swing landed in 2022, when Common Equity surged 489.55%; it then slumped 597.3% in 2024.
- Tracing PVLA's Common Equity over 5 years: stood at -$93.8 million in 2022, then advanced by 20.57% to -$74.5 million in 2023, then surged by 184.06% to $62.6 million in 2024, then tumbled by 55.3% to $28.0 million in 2025, then jumped by 730.19% to $232.3 million in 2026.
- Per Business Quant, the three latest PVLA Common Equity figures stand at $232.3 million (Q1 2026), $28.0 million (Q4 2025), and $38.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | 232.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 232.31 Mn |
| Dec 31, 2025 | 27.98 Mn |
| Sep 30, 2025 | 38.68 Mn |
| Jun 30, 2025 | 47.78 Mn |
| Mar 31, 2025 | 55.58 Mn |
| Dec 31, 2024 | 62.61 Mn |
| Sep 30, 2024 | -87.40 Mn |
| Jun 30, 2024 | -80.83 Mn |
| Mar 31, 2024 | -76.87 Mn |
| Dec 31, 2023 | -74.48 Mn |
| Sep 30, 2023 | 30.51 Mn |
| Jun 30, 2023 | 40.50 Mn |
| Mar 31, 2023 | 15.46 Mn |
| Dec 31, 2022 | -93.78 Mn |
| Sep 30, 2022 | 317.49 Mn |
| Jun 30, 2022 | 44.37 Mn |
| Mar 31, 2022 | 53.45 Mn |
| Dec 31, 2021 | 50.76 Mn |
| Sep 30, 2021 | 53.85 Mn |
| Jun 30, 2021 | 46.72 Mn |
| Mar 31, 2021 | 38.24 Mn |
| Dec 31, 2020 | 31.03 Mn |
| Sep 30, 2020 | 43.69 Mn |
| Jun 30, 2020 | 46.67 Mn |
| Mar 31, 2020 | 49.81 Mn |
| Dec 31, 2019 | 51.35 Mn |
| Sep 30, 2019 | 20.64 Mn |
| Jun 30, 2019 | 19.49 Mn |
| Mar 31, 2019 | 30.16 Mn |
| Dec 31, 2018 | 39.94 Mn |
| Sep 30, 2018 | 50.26 Mn |
| Jun 30, 2018 | 55.32 Mn |
| Mar 31, 2018 | 50.69 Mn |
| Dec 31, 2017 | 11.52 Mn |
| Sep 30, 2017 | 4.56 Mn |
| Jun 30, 2017 | 9.33 Mn |
| Mar 31, 2017 | 18.04 Mn |
| Dec 31, 2016 | 25.23 Mn |
| Sep 30, 2016 | 31.48 Mn |
| Jun 30, 2016 | 37.29 Mn |
| Mar 31, 2016 | 27.18 Mn |
| Dec 31, 2015 | 31.13 Mn |
| Sep 30, 2015 | 33.65 Mn |
| Jun 30, 2015 | 11.15 Mn |
| Mar 31, 2015 | 14.23 Mn |
| Dec 31, 2014 | 18.01 Mn |
| Sep 30, 2014 | -904.00 |
| Jun 30, 2014 | 10,014.00 |
| Mar 31, 2014 | -4,778.00 |
| Dec 31, 2013 | 585,007.00 |
| Jun 30, 2013 | 4,726.00 |